Integration of genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic leukaemia with intermediate MRD levels at the end of induction-Reference-Cited by-同舟云学术

Integration of genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic leukaemia with intermediate MRD levels at the end of induction

Published:2024-07-05 Issue:9 Volume:38 Page:2023-2026
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Moorman Anthony V.^ORCID,Enshaei Amir^ORCID,Murdy Daniel,Joy Melvin^ORCID,Boer Judith M.^ORCID,den Boer Monique L.^ORCID,Pieters Rob^ORCID,de Haas Valerie^ORCID,Horstmann Martin A.^ORCID,Escherich Gabriele,Johansson Bertil^ORCID,Marquart Hanne V.^ORCID,Schmiegelow Kjeld^ORCID,Hancock Jeremy,Moppett John^ORCID,Heyman Mats^ORCID

Funder

Cancer Research UK

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41375-024-02329-0.pdf

Reference15 articles.

1. Pieters R, de Groot-Kruseman H, Van der Velden V, Fiocco M, van den Berg H, de Bont E, et al. Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL10 from the Dutch Childhood Oncology Group. J Clin Oncol. 2016;34:2591–601.

2. O’Connor D, Enshaei A, Bartram J, Hancock J, Harrison CJ, Hough R, et al. Genotype-specific minimal residual disease interpretation improves stratification in pediatric acute lymphoblastic leukemia. J Clin Oncol. 2018;36:34–43.

3. O’Connor D, Moorman AV, Wade R, Hancock J, Tan RM, Bartram J, et al. Use of Minimal Residual Disease Assessment to Redefine Induction Failure in Pediatric Acute Lymphoblastic Leukemia. J Clin Oncol. 2017;35:660–7.

4. Toft N, Birgens H, Abrahamsson J, Griskevicius L, Hallbook H, Heyman M, et al. Results of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemia. Leukemia 2018;32:606–15

5. Buchmann S, Schrappe M, Baruchel A, Biondi A, Borowitz M, Campbell M, et al. Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium. Blood. 2022;139:1785–93.